Pharmacosmos Therapeutics

Pharmacosmos Therapeutics is a specialty pharmaceutical company focused on the treatment of iron deficiency and iron deficiency anemia. As the US subsidiary of the Danish-based Pharmacosmos A/S, the company specializes in the development and commercialization of high-dose intravenous iron therapies. Its flagship product, Monoferric (ferric derisomaltose), is indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as those with non-dialysis dependent chronic kidney disease. The company is dedicated to improving patient outcomes through innovative carbohydrate chemistry and iron therapy solutions.